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Industry relation-
ships, when man-
aged properly, are
crucial in terms of
advancing the
quality of care for
patients.
It is the College’s
hope that by devel-
oping rigorous and
transparent stan-
dards that we can
create a culture of
openness in order to
rebuild trust in our
health care system
and avoid pressing
threats to physician
autonomy.uch has been made over the last few years about conflicts of interest in
the medical community’s relationships with industry. This includes both
relationships with individual physicians as well as those with academic
edical centers and professional organizations.
The American College of Cardiology (ACC) is committed to professionalism and
o a transparent relationship with all of our industry sources of funding. We have
mong the most stringent policies in place in the medical community to ensure that
upport from industry has no influence on any of our clinical documents, such as
ractice guidelines and appropriate use criteria, or the content of the medical educa-
ion we sponsor.
Our “Principles for Relationships With Industry” (1) serve as the organization’s
uide in nine key areas of operation: 1) advertising; 2) charitable donations; 3) clini-
al document development; 4) continuing medical education; 5) exposition; 6) gover-
ance; 7) government grants and foundation support; 8) registries; and 9) sponsor-
hips. As the ACC President and the Chair of the Science and Clinical Policy
ubcommittee, we are proud of this commitment to full transparency and the very
ighest ethical standards.
When it comes to industry, properly managed partnerships are absolutely critical
o maintaining scientific progress in cardiology and other specialties. While some in
ongress, the medical community, the lay press, and elsewhere have suggested that
here should be absolutely no use of industry funds for any medical school or orga-
ization activity, given the scarcity of public funding for research and publications
nd the relatively high cost of education, this position would make it very difficult
or medical societies to carry out their missions and enhance quality of care. In fact,
e believe that industry, in addition to its role in developing new drugs and devices
hat advance the treatment of cardiovascular disease, has an obligation and expecta-
ion to provide funding for the education of practitioners as part of its social con-
ract with patients, clinicians, and society as a whole.
In the case of the ACC, we rely on industry funding to advance cardiovascular
esearch as well as cardiovascular workforce training, practitioner diversity, medical
ducation, and lifelong learning. Without this funding, our efforts to provide mean-
ngful, unbiased education and to improve quality of care would be far more limited
han what we currently offer to members and ultimately our patients. Rather than
estricting industry funding for such activities, we should instead focus on transpar-
ncy and actively and appropriately managing industry relationships.
Disclosure is critical. The College has strict organizational firewalls between the
evelopment and fundraising related to commercial support and the College’s pro-
rammatic activities and personnel. These firewalls are designed to ensure that the
CC’s relationships with drug and device companies would never influence the sci-
ntific or educational content the College produces. In addition, the ACC adheres
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ompanies providing support from exercising any influ-
nce or control over programmatic content, speaker/
aculty selection, program format, planning, partnering
rrangements, program evaluation methods, and related
atters.
Most recently, the College reaffirmed its commit-
ent to transparency by signing the “Code for Interac-
ions with Companies,” released by the Council of
edical Specialty Societies (2). The code is meant to
ncrease transparency and set a universal standard for
ndependent program development and independent
eadership. The ACC made significant contributions to
he final code, based on our own relationships with
ndustry principles.
In addition, the College has developed new princi-
les related to the development of clinical documents,
uch as guidelines, scientific advisories, and appropriate
se criteria. We consider guideline and clinical docu-
ent development critical to our mission, and these
ew principles are designed to ensure that authors in-
olved in the development of clinical documents fully
isclose all relationships with industry and other enti-
ies to eliminate the possibility of undue bias. The
readth of disclosures include research funding, con-
ulting relationships, stock ownership, advisory boards,
ata safety monitoring boards, and uncompensated po-
ential “intellectual conflicts.” We have worked collabo-
atively with the American Heart Association (AHA)
o ensure our relationships with industry policies on
ocument creation are identical.
Under the new principles, all clinical document au-
hors, including organizational representatives of Amer-
can College of Cardiology Foundation (ACCF) docu-
ent writing committees (e.g., guidelines, performance
easures, clinical alerts, scientific statements, and ex-
ert consensus documents), must annually disclose all
elationships with industry and other entities using the
CC’s Electronic Disclosure Database. In addition, all
CCF writing committees must have a chair without
ny relationships that are relevant to the document un-
er development. The respective ACCF parent task
orces responsible for overseeing clinical practice guide-
ines, expert consensus documents, appropriate use cri-
eria, and so on, must review and approve all writing
ommittee appointments and adjudicate questions or
oncerns relating to relationships with industry.
The ACC’s Clinical Quality Committee’s Science
nd Clinical Policy Subcommittee has taken on the
entral role of addressing broad conflicts of interest
ssues. When it comes to writing committees, each lommittee must have at least 50% of its members (ex-
luding the chair) without relevant industry relation-
hips. This means that the responsibility for identifying
embers without relevant relationships is distributed
as evenly and fairly as possible) to all partnering orga-
izations. Partners or collaborating organizations are
sked to recommend several alternate representatives to
acilitate the implementation of this policy. If there is
ifficulty in reaching the 50/50 distribution of members
ith and without relationships, organizations are asked
or alternative names until even distribution is reached.
It is important to note that there may be times dur-
ng the document generation process where it is advis-
ble to have writing group members with relevant in-
ustry relationships in order to ensure the scientific
igor related to certain areas of content. In these situa-
ions, the ACC and the AHA have strict policies in
lace related to recusing an individual or individuals
ith industry relationships from any text drafting of
elevant document sections and/or from voting on any
ecommendation relevant to their relationship(s). Fi-
ally, relevant industry relationships for all writing
ommittees are published with the document and
comprehensive” documentation is also available
lectronically.
The College recognizes that the new principles govern-
ng development of clinical policy documents are contro-
ersial. While some view these policies as too constricting,
aking ideal document creation quite challenging, others
iew these policies as not strict enough. We do know that
hese new policies have added time and complexity to the
lready difficult process of commissioning writing com-
ittees and have potential impacts on partnering/collabo-
ating organizations. It also means that the distribution of
embers with and without relationships with industry
ay not always be evenly distributed among partner/col-
aborating organizations. That being said, we are commit-
ed to these new principles and believe that these changes
ill not dilute the rigor and science behind the clinical
ocument development process. Rather, transparency and
rigorous process to manage relationships with industry
s the best policy for everyone involved in the develop-
ent of organizational documents and standards.
Industry relationships, when managed properly, are
rucial in terms of advancing the quality of care for
atients. We need to help the media, the public, and
olicymakers better understand the beneficial role of
ndustry in promoting research, education, and innova-
ion in medicine. We also need to be out in front ad-
ising them when their words or actions related to re-
ationships with industry issues may be misguided
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he best possible evidence-based documents. It is the
ollege’s hope that by developing rigorous and trans-
arent standards that we can create a culture of open-
ess in order to rebuild trust in our health care system
nd avoid pressing threats to physician autonomy. Our
ltimate job is to make sure that any relationship is
anaged in a way that ensures unbiased, evidence-
ased, and balanced reviews of science, regardless of
unding sources.
More information on the ACC’s relationships with
ndustry principles, as well as the disclosures of trustees,
tate chapter governors, and committee chairs, is available
n the ACC’s web site (CardioSource.org).ddress correspondence to:
alph Brindis, MD, MPH, FACC
merican College of Cardiology
400 N Street NW
ashington, DC 20037
-mail: rbrindis@acc.org
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